Table 2.
Ongoing randomized trials of temporary MCS in AMI-CS.
| Name | NCT No. | Started recruiting | Projected N | Intervention |
|---|---|---|---|---|
| Populations with AMI-CS | ||||
| ECLS-SHOCK | NCT03637205 | Yes | 420 | VA-ECMO |
| EUROSHOCKa | NCT03813134 | Yes | 428 | VA-ECMO |
| ANCHOR | NCT04184635 | Yes | 400 | VA-ECMO |
| DanGer Shock | NCT01633502 | Yes | 360 | Impella CP |
| ULYSS | NCT05366452 | No | 204 | Impella CP |
| RECOVER-IV | NCT05506449 | No | 560 | Impella CP |
| Patients with CS receiving ECMO | ||||
| REVERSE | NCT03431467 | Yes | 96 | Impella CP |
| UNLOAD ECMO | NCT05577195 | No | 198 | Impella CP |
| ECMOsorb | NCT05027529 | Yes | 54 | Cytosorb |
| AMI + preshock | ||||
| SCAI-B | NCT04989777 | No | 512 | IABP |
AMI-CS, acute myocardial infarction-cardiogenic shock; CS, cardiogenic shock; ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; VA-ECMO, venoarterial extracorporeal membrane oxygenation.
From clinicaltrials.gov search on October 31, 2022.
a
This study was terminated early owing to slow recruitment and other factors.